204 related articles for article (PubMed ID: 36982605)
1. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
3. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
4. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
Wu W; Grohganz H; Rades T; Löbmann K
Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
[TBL] [Abstract][Full Text] [Related]
5. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
[TBL] [Abstract][Full Text] [Related]
6. Potential application of low molecular weight excipients for amorphization and dissolution enhancement of carvedilol.
Pešić N; Dapčević A; Ivković B; Kachrimanis K; Mitrić M; Ibrić S; Medarević D
Int J Pharm; 2021 Oct; 608():121033. PubMed ID: 34419592
[TBL] [Abstract][Full Text] [Related]
7. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
Laitinen R; Löbmann K; Grohganz H; Strachan C; Rades T
Mol Pharm; 2014 Jul; 11(7):2381-9. PubMed ID: 24852326
[TBL] [Abstract][Full Text] [Related]
8. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
9. Tranilast-matrine co-amorphous system: Strong intermolecular interactions, improved solubility, and physiochemical stability.
Hu D; Chen X; Li D; Zhang H; Duan Y; Huang Y
Int J Pharm; 2023 Mar; 635():122707. PubMed ID: 36764418
[TBL] [Abstract][Full Text] [Related]
10. Dipeptides as co-formers in co-amorphous systems.
Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Rades T; Grohganz H
Eur J Pharm Biopharm; 2019 Jan; 134():68-76. PubMed ID: 30468836
[TBL] [Abstract][Full Text] [Related]
11. Sulfonic Acid Derivatives in the Production of Stable Co-Amorphous Systems for Solubility Enhancement.
da Costa NF; Santos IA; Fernandes AI; Pinto JF
J Pharm Sci; 2022 Dec; 111(12):3327-3339. PubMed ID: 36007560
[TBL] [Abstract][Full Text] [Related]
12. Poly (amino acid)s as new co-formers in amorphous solid dispersion.
Huang Q; Zou Z; Li X; Xiao Q; Liang G; Wu W
Int J Pharm; 2023 Mar; 634():122645. PubMed ID: 36706970
[TBL] [Abstract][Full Text] [Related]
13. Co-Amorphous Formation of High-Dose Zwitterionic Compounds with Amino Acids To Improve Solubility and Enable Parenteral Delivery.
Zhu S; Gao H; Babu S; Garad S
Mol Pharm; 2018 Jan; 15(1):97-107. PubMed ID: 29164901
[TBL] [Abstract][Full Text] [Related]
14. Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.
Khanfar M; Al-Remawi M; Al-Akayleh F; Hmouze S
AAPS PharmSciTech; 2021 Mar; 22(3):112. PubMed ID: 33748914
[TBL] [Abstract][Full Text] [Related]
15. Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin.
Ojarinta R; Heikkinen AT; Sievänen E; Laitinen R
Eur J Pharm Biopharm; 2017 Mar; 112():85-95. PubMed ID: 27888143
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
17. Non-salt based co-amorphous formulation produced by freeze-drying.
Suleiman Alsalhi M; Royall PG; Al-Obaidi H; Alsalhi A; Cilibrizzi A; Chan KLA
Int J Pharm; 2023 Oct; 645():123404. PubMed ID: 37714312
[TBL] [Abstract][Full Text] [Related]
18. Co-former selection for co-amorphous drug-amino acid formulations.
Kasten G; Löbmann K; Grohganz H; Rades T
Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980
[TBL] [Abstract][Full Text] [Related]
19. Co-amorphization of atorvastatin by lisinopril as a co-former for solubility improvement.
Li W; Song J; Li J; Li M; Tian B; He Z; Liu X; Fu Q
Int J Pharm; 2021 Sep; 607():120971. PubMed ID: 34363915
[TBL] [Abstract][Full Text] [Related]
20. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
Fael H; Demirel AL
Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
